Results 41 to 50 of about 1,616,748 (350)

A pan-immune panorama of bacterial pneumonia revealed by a large-scale single-cell transcriptome atlas

Signal Transduction and Targeted Therapy
Bacterial pneumonia is a significant public health burden, contributing to substantial morbidity, mortality, and healthcare costs. Current therapeutic strategies beyond antibiotics and adjuvant therapies are limited, highlighting the need for a deeper ...
Kun Xiao, Yan Cao, Zhihai Han, Yuxiang Zhang, L. Luu, Liang Chen, Peng Yan, Wei Chen, Jiaxing Wang, Ying Liang, Xin Shi, Xiuli Wang, Fan Wang, Ye Hu, Zhengjun Wen, Yong Chen, Yuwei Yang, Haotian Yu, Lixin Xie, Yi Wang   +19 more
semanticscholar   +1 more source

Incidence of Invasive Group A Streptococcal Infections and Comparison of emm Types from Carriage, Pharyngitis, and Invasive Infections in Indigenous Communities in the Southwest United States

Proceedings
Background: Indigenous communities are disproportionately affected by group A Streptococcus (GAS) infections [...]
Catherine G. Sutcliffe, Victoria M. Sergent, Joyselynn Pitalua, Sopio Chochua, Christopher J. Gregory, Chloe Hurley, Zhongya Li, Saundra Mathis, Lesley McGee, Jennifer Onukwube Okaro, Theresa Tran, Robert Weatherholtz, Laura L. Hammitt   +12 more
doaj   +1 more source

Comparison of Short- versus Long-Course Antimicrobial Therapy of Uncomplicated Bacterial Pneumonia in Dogs: A Double-Blinded, Placebo-Controlled Pilot Study

Animals, 2021
Current treatment for canine bacterial pneumonia relies on protracted courses of antimicrobials (3–6 weeks or more) with recommendations to continue for 1–2 weeks past resolution of all clinical and thoracic radiographic abnormalities. However, in humans,
Aida I. Vientós-Plotts, Isabelle Masseau, Carol R. Reinero   +2 more
doaj   +1 more source

Omadacycline for Community‐Acquired Bacterial Pneumonia

New England Journal of Medicine, 2019
BACKGROUND Omadacycline, a new once‐daily aminomethylcycline antibiotic agent that can be administered intravenously or orally, reaches high concentrations in pulmonary tissues and is active against common pathogens that cause community‐acquired ...
R. Stets, M. Popescu, J. Gonong, I. Mitha, W. Nseir, A. Madej, Courtney Kirsch, Anita F. Das, L. Garrity-Ryan, J. Steenbergen, A. Manley, P. Eckburg, E. Tzanis, P. Mcgovern, E. Loh   +14 more
semanticscholar   +1 more source

SARS-CoV-2-related pneumonia cases in pneumonia picture in Russia in March-May 2020: Secondary bacterial pneumonia and viral co-infections

Journal of Global Health, 2020
Background We are communicating the results of investigating statistics on SARS-CoV-2-related pneumonias in Russia: percentage, mortality, cases with other viral agents, cases accompanied by secondary bacterial pneumonias, age breakdown, clinical course ...
K. Sharov
semanticscholar   +1 more source

NLRP6 Modulates Neutrophil Homeostasis in Bacterial Pneumonia-Derived Sepsis

Mucosal Immunology, 2020
Bacterial pneumonia is a significant cause of morbidity, mortality, and health care expenditures. Optimum neutrophil recruitment and their function are critical defense mechanisms against respiratory pathogens.
S. Cai, Sagar Paudel, Liliang Jin, Laxman Ghimire, Christopher M. Taylor, N. Wakamatsu, Dinesh Bhattarai, S. Jeyaseelan   +7 more
semanticscholar   +1 more source

Bacterial co-infections in community-acquired pneumonia caused by SARS-CoV-2, influenza virus and respiratory syncytial virus

BMC Infectious Diseases, 2022
Background A mismatch between a widespread use of broad-spectrum antibiotic agents and a low prevalence of reported bacterial co-infections in patients with SARS-CoV-2 infections has been observed . Herein, we sought to characterize and compare bacterial
Pontus Hedberg, N. Johansson, A. Ternhag, Lina Abdel-Halim, J. Hedlund, P. Nauclér   +5 more
semanticscholar   +1 more source

Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial

Clinical Infectious Diseases, 2019
Monotherapy with lefamulin, a novel, pleuromutilin antibiotic with intravenous and oral formulation options, was noninferior to moxifloxacin for efficacy and generally safe and well tolerated for community-acquired bacterial pneumonia (CABP). Lefamulin’s
T. File, L. Goldberg, Anita F. Das, Carolyn Sweeney, John Saviski, S. Gelone, E. Seltzer, S. Paukner, W. Wicha, G. Talbot, L. Gasink   +10 more
semanticscholar   +1 more source

Fungal pneumonia concealing bacterial pneumonia: a diagnostic dilemma

Monaldi Archives for Chest Disease, 2023
We describe the case of a 61-year-old diabetic man affected by Achromobacter denitrificans. He was immunocompetent and did not have any past history of chronic lung disease.
Christie George Joseph, Madhusmita Mohanty Mohapatra, Manju Rajaram, Jayabharathi Palanivel, Balasubramanian Velappan   +4 more
doaj   +1 more source

Assessing Animal Models of Bacterial Pneumonia Used in Investigational New Drug Applications for the Treatment of Bacterial Pneumonia

Antimicrobial Agents and Chemotherapy, 2020
Animal models of bacterial infection have been widely used to explore the in vivo activity of antibacterial drugs. These data are often submitted to the U.S.
Ursula Waack, E. Weinstein, J. Farley
semanticscholar   +1 more source